Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-924 Phase III confirmatory study in hypercholesterolemia
jRCT2080225092Phase 3Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of K-924 in hypercholesterolemia (4 arms), sponsored by Kowa Company, Ltd. Primary endpoints: Percent change from baseline in LDL-C at 12 weeks (K-924 HD vs pitavastatin 4 mg), Percent change from baseline in LDL-C at 12 weeks (K-924 LD vs pitavastatin 2 mg) and 1 more. Started Feb 2020; status: completed.
02
Drugs
K-924
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on jRCT2080225092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225092.